PNEUMOVAX® 23
splenectomy are at increased risk for fulminant pneumococcal sepsis associated .... reports, pneumococcal vaccine may be given as early as several months ....
Other adverse experiences reported in clinical trials and/or in post-marketing
experience with .... Unpublished data; files of Merck Research Laboratories. ...
http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23...
|
Protein A Columns for Immune Thrombocytopenia: Health Technology ...
OHTA is one component of the Agency for Health Care Policy and Research (AHCPR), ... However, no such system is currently approved for marketing by the Food and
Drug .... Splenectomy, which removes the principle site of platelet destruction
and ... A recent report by Muroi et al, (47). involved the use of protein A ...
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive...
|
GSK reports Promacta®/Revolade® (eltrombopag) significantly ...
6 Dec 2008 ... GSK submitted a Marketing Authorisation Application (MAA) for eltrombopag in Europe ... Eltrombopag was discovered as a result of a research ...
http://www.gsk.com/media/pressreleases/2008/2008_pressreleas...
|
New Report Just Published: World Endoscopy Systems Market Report
Company profiles are mostly extracted from URL research and reported select online sources. ... Ulcer Treatment II-34 Laparoscopic Splenectomy II-34 Splenic
Aneurysms II-34 ..... More market research reports here! SOURCE Reportlinker ...
http://www.prnewswire.com/news-releases/new-report-just-publ...
|
Study analysis shows that eltrombopag significantly improves ...
Please note that this release may not have been issued in every market in which GSK ... responding ITP patients including those with prior splenectomy or those
having a ... Eltrombopag was discovered as a result of a research collaboration
... and Financial Review and Prospects' in the company's Annual Report 2005. ...
http://www.gsk.com/media/pressreleases/2006/2006_06_19_GSK85...
|
Amgen's Pivotal Phase 3 Romiplostim Study in Splenectomized ...
Sixty-three splenectomized patients were enrolled (placebo, 21; romiplostim, .... Our stock price may be affected by actual or perceived market opportunity,
...
http://www.biospace.com/news_story.aspx?NewsEntityId=79905...
|
GSK initiates repeat dosing study of its novel oral platelet ...
12 Apr 2007 ... examples of which include splenectomy, corticosteroids, immunoglobulins, cyclophosphamide and rituximab. ... Eltrombopag was discovered as a result of a
research collaboration ... approval in any market for any indication at this
time. ... in the company's Annual Report on Form 20-F for 2006. ...
http://www.gsk.com/media/pressreleases/2007/2007_04_12_GSK10...
|
Amgen's Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized ...
11 Dec 2007 ... Randomized Phase 3 Study of Nplate in Non-Splenectomized Patients (Abstract #565 ) ... M.D., director of Platelet Research, Weill Medical College, ... including
Amgen's most recent annual report on Form 10-K and most recent periodic ... Our
stock price may be affected by actual or perceived market ...
http://www.biospace.com/news_story.aspx?NewsEntityId=80112...
|
HIV, visceral leishmaniasis and Parkinsonism combined with ...
1Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical ... We hereby report an unusual case presentation of Visceral ...
Splenic aspirate for Leishman Donovan bodies was 3+ according to WHO criteria.
... Recently fusion inhibitors are coming up in the world market but their main
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561008/...
|
GlaxoSmithKline files for FDA approval of Promacta/Revolade ...
20 Dec 2007 ... GSK also plans to submit a Marketing Authorisation Application (MAA) for eltrombopag in Europe in 2008. ... such as corticosteroids, immunoglobulins and/
or splenectomy. ... GlaxoSmithKline — one of the world's leading research-based
... Review' in the company's Annual Report on Form 20-F for 2006. ...
http://www.gsk.com/media/pressreleases/2007/2007_12_20_GSK11...
|
